Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 5/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.37 |
| ▸ | ANPEP | P15144 | 2/20 | 0.37 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23066886 | 0.76 | LAP3 (0.46) | LAP3PIN1ANPEPACP3TSHR | |
| SCHEMBL3428434 | 0.75 | ADRB2 (0.40) | POLBTRPA1 | |
| SCHEMBL3428431 | 0.75 | ADRB2 (0.40) | POLBTRPA1 | |
| SCHEMBL4698511 | 0.74 | CYP1A2 (0.54) | — | |
| SCHEMBL31480850 | 0.72 | BTN3A1 (0.39) | BTN3A1TSHRHMGCR | |
| SCHEMBL8917840 | 0.72 | TRPA1 (0.41) | MAPTTRPA1 | |
| SCHEMBL5788640 | 0.72 | EPHX1 (0.50) | ANPEP | |
| SCHEMBL7663381 | 0.71 | TAAR1 (0.37) | BTN3A1TSHR | |
| SCHEMBL8710569 | 0.71 | FOLH1 (0.43) | ANPEPPOLB | |
| SCHEMBL6349630 | 0.70 | CSNK1E (0.47) | LAP3ANPEPTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210070698-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070698-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | LAP3 799/4885PIN1 130/4885ANPEP 745/4885 |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | LAP3 799/4885PIN1 130/4885ANPEP 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.